All In Biotech

Drug Trial Radar · NCT05468489

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Nov 18, 2022

Primary completion

Feb 28, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Jul 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)

Conditions

  • Extensive Stage Small Cell Lung Cancer

Interventions

  • Serplulimab + chemotherapy (carboplatin-etoposide)Drug

    Drug: Serplulimab is an innovative monoclonal antibody targeting PD-1,developed by Shanghai Henlius Biotech, Inc. Drug: carboplatin and etoposide chemotherapeutics

  • Atezolizumab + chemotherapy (carboplatin-etoposide)Drug

    Drug: Atezolizumab is a monoclonal antibody targeting PD-L1,developed by Roche Pharma AG. Drug: carboplatin and etoposide chemotherapeutics

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. OSTime frame: A period from randomization through death regardless of causality (approximately up to 24 months).

Locations

65 sites in 1 country. Site status is shown where the registry gives one.

  • Alabama Oncology

    Birmingham, Alabama

  • City of Hope - Phoenix

    Goodyear, Arizona

  • Arizona Clinical Research Center (ACRC)

    Tucson, Arizona

  • Highlands Oncology Group

    Springdale, Arkansas

  • Compassionate Care Research Group

    Fountain Valley, California

  • Providence Medical Foundation

    Fullerton, California

  • Los Angeles Cancer Network

    Glendale, California

  • OPN - Oncology Physician Network

    Los Alamitos, California

  • Kaiser Permanente Research (Southern California)

    Los Angeles, California

  • UC Davis

    Sacramento, California

  • UCHealth Memorial Hospital North

    Colorado Springs, Colorado

  • MD Anderson- North Colorado Medical Center

    Greeley, Colorado

  • Advanced Cancer Treatment Centers

    Brooksville, Florida

  • Cancer Specialists North Florida

    Jacksonville, Florida

  • Mount Sinai Comprehensive Cancer Center

    Miami, Florida

  • Florida Cancer Affiliates- (Ocala Oncology - Main)

    Ocala, Florida

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida

  • BRCR Global

    Plantation, Florida

  • Napa Research

    Pompano Beach, Florida

  • Advanced Research

    Tamarac, Florida

  • Straub Benioff Medical Center

    Honolulu, Hawaii

  • City of Hope- Chicago

    Chicago, Illinois

  • Cancer Center of Decatur

    Decatur, Illinois

  • Accellacare of Duly

    Tinley Park, Illinois

  • Northwest Cancer Centers

    Dyer, Indiana

  • Cancer Center of Kansas

    Wichita, Kansas

  • Baptist Health Lexington

    Lexington, Kentucky

  • Pikeville Hospital

    Pikeville, Kentucky

  • CHRISTUS St. Frances Cabrini Cancer Center

    Alexandria, Louisiana

  • Pontchartrain Cancer Center

    Hammond, Louisiana

  • Henry Ford Health Providence Southfield Hospital

    Southfield, Michigan

  • Health Partners Cancer Center at Regions Hospital

    Saint Paul, Minnesota

  • Hattiesburg Clinic Hematology/Oncology

    Hattiesburg, Mississippi

  • MidAmerica Division Inc., c/o Research Medical Center

    Kansas City, Missouri

  • Lake Regional

    Osage Beach, Missouri

  • St. Vincent Frontier Cancer Center

    Billings, Montana

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Renown Health

    Reno, Nevada

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire

  • Regional Cancer Care Associates LLC RCCA

    Freehold, New Jersey

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.